![]() | This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||
|
![]() | The following Wikipedia contributor may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include
conflict of interest,
autobiography, and
neutral point of view.
|
Suggested addition to article:
"In June 2013, Immunocore signed a deal with Genentech, worth between $10 and $30 million per programme, for the discovery and development of cancer treatments
Cite error: There are <ref>
tags on this page without content in them (see the
help page).
http://www.fiercebiotech.com/press-releases/immunocore-and-genentech-enter-strategic-alliance-develop-immtacs-multiple"
Cite error: There are <ref>
tags on this page without content in them (see the
help page).
http://www.independent.co.uk/news/science/exclusive-cancer--a-cure-just-got-closer-thanks-to-a-tiny-british-company--and-the-result-could-change-lives-of-millions-8707590.html
Pool59 (
talk)
12:48, 22 July 2013 (UTC)
Immunocore’s novel bispecific biologics are based on precision-engineered, soluble T cell receptors, known as ImmTACs (Immune mobilising mTCR Against Cancer).
Cite error: There are <ref>
tags on this page without content in them (see the
help page).
http://www.nature.com/nm/journal/v18/n6/full/nm.2764.html
Cite error: There are <ref>
tags on this page without content in them (see the
help page).
http://www.landesbioscience.com/journals/oncoimmunology/article/22891/
Pool59 (
talk)
14:35, 2 August 2013 (UTC)
I am going to be bold and make some changes to the article which I believe will improve it. First of all, the history should come before the discussion of the background scientific information explaining what the company does. So I am just moving history to the top. After I do that, I will see what other improvements can be made. Feelingfancyfree ( talk) 09:04, 29 April 2015 (UTC)
Professor Lucy Dorrell and her team at the University of Oxford worked with Immunocore Ltd - a UK biotechnology company based in Oxfordshire - to investigate the potency of novel engineered immune-mobilising T cell receptors-based drugs ('ImmTAVs'), designed to clear HIV-infected cells.
I suggest that we consider including this revolutionary development in the article. [1] [2] [3] They are being used also for zika infection. MaynardClark ( talk) 21:53, 22 July 2016 (UTC)
References